Company news
Oryzon Genomics SA news in 2020
Oryzon Genomics SA's news releases, calls and decks from 2020, newest first.
ORYZON Presents New Robust Phase II Iadademstat Efficacy Data in AML at ASH-2020
December 7, 2020
ORYZON Receives Approval to Start PORTICO Phase IIb Trial with Vafidemstat in Borderline Personality Disorder
November 10, 2020
Oryzon Announces Appointment of Dr. Torsten Hoffmann as Global R&D Director and Retirement of Dr. Tamara Maes
November 2, 2020
ORYZON Reports Results for Quarter Ended September 30, 2020 and Provides Corporate Update
October 26, 2020
ORYZON Publishes Paper in Journal of Clinical Oncology Demonstrating Relevance of Iadademstat in Leukemia
October 15, 2020
ORYZON First Half Ended June 30, 2020 Results and Corporate Update
July 22, 2020
ORYZON Raises its Share Capital by EUR 20 Million
July 7, 2020
ORYZON Enters Into Pioneering Precision Medicine Collaboration with La Paz Hospital in Madrid for Phelan-McDermid Syndrome
June 19, 2020
ORYZON to Present Additional Efficacy Clinical Data From ALICE Phase IIa Trial with Iadademstat at the 25th Congress of the European Hematology Association
June 2, 2020
ORYZON Publishes Characterization and Mechanism of Action of Vafidemstat, a Phase II Clinical Stage LSD1 Inhibitor, in PLOS ONE
June 1, 2020
ORYZON Announces Enrollment of First Patient in ESCAPE: a Phase II Clinical Trial with Vafidemstat in Severely Ill COVID-19 Patients
May 18, 2020
ORYZON Appoints Manuel López-Figueroa of Bay City Capital to its Board of Directors
May 11, 2020
ORYZON First Quarter 2020 Results and Corporate Update
May 11, 2020
ORYZON to Initiate ESCAPE: a Phase II Clinical Trial to Test Efficacy of Vafidemstat in Severely ill COVID-19 Patients
April 24, 2020
ORYZON Provides a Corporate Update in the Context of COVID-19
April 17, 2020
ORYZON Appoints Eisai Executive Vanessa Almendro Navarro to Board of Directors
April 17, 2020
ORYZON Presents Efficacy Data From its Two Vafidemstat Clinical Trials in Alzheimer’s Disease at the Virtual AAT-AD/PD 2020 Conference
April 3, 2020
ORYZON Reports Financial Results and Corporate Update for 4th Quarter and Year Ended December 31, 2019
February 24, 2020
ORYZON to Present at the 3rd Neuroscience Innovation Forum in San Francisco
January 8, 2020
Decks in 2020
- Technical Presentation (April 2020)
Technical · 26 slides · Apr 3, 2020